| Heart disease and stroke statistics—2014 update: a report from the American Heart Association AS Go, D Mozaffarian, VL Roger, EJ Benjamin, JD Berry, MJ Blaha, S Dai, ... circulation 129 (3), e28-e292, 2014 | 63052* | 2014 |
| Apixaban versus warfarin in patients with atrial fibrillation CB Granger, JH Alexander, JJV McMurray, RD Lopes, EM Hylek, ... New England Journal of Medicine 365 (11), 981-992, 2011 | 12106 | 2011 |
| 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation developed … Authors/Task Force Members, AJ Camm, GYH Lip, R De Caterina, ... European heart journal 33 (21), 2719-2747, 2012 | 6842 | 2012 |
| Initial invasive or conservative strategy for stable coronary disease DJ Maron, JS Hochman, HR Reynolds, S Bangalore, SM O’Brien, ... New England Journal of Medicine 382 (15), 1395-1407, 2020 | 2706 | 2020 |
| Sotagliflozin in patients with diabetes and recent worsening heart failure DL Bhatt, M Szarek, PG Steg, CP Cannon, LA Leiter, DK McGuire, ... New England journal of medicine 384 (2), 117-128, 2021 | 2018 | 2021 |
| Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial AF Hernandez, JB Green, S Janmohamed, RB D'Agostino, CB Granger, ... The Lancet 392 (10157), 1519-1529, 2018 | 1777 | 2018 |
| Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials N Sattar, MMY Lee, SL Kristensen, KRH Branch, S Del Prato, NS Khurmi, ... The lancet Diabetes & endocrinology 9 (10), 653-662, 2021 | 1569 | 2021 |
| Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial BM Tomazini, IS Maia, AB Cavalcanti, O Berwanger, RG Rosa, VC Veiga, ... Jama 324 (13), 1307-1316, 2020 | 1522 | 2020 |
| Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo … PM Ridker, JG MacFadyen, T Thuren, BM Everett, P Libby, RJ Glynn, ... The Lancet 390 (10105), 1833-1842, 2017 | 1508 | 2017 |
| Apixaban with antiplatelet therapy after acute coronary syndrome JH Alexander, RD Lopes, S James, R Kilaru, Y He, P Mohan, DL Bhatt, ... New England Journal of Medicine, 2011 | 1429 | 2011 |
| Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation RD Lopes, G Heizer, R Aronson, AN Vora, T Massaro, R Mehran, ... New England Journal of Medicine 380 (16), 1509-1524, 2019 | 1391 | 2019 |
| Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19 AB Cavalcanti, FG Zampieri, RG Rosa, LCP Azevedo, VC Veiga, ... New England Journal of Medicine 383 (21), 2041-2052, 2020 | 1382 | 2020 |
| LOSITAN: A workbench to detect molecular adaptation based on a Fst-outlier method T Antao, A Lopes, RJ Lopes, A Beja-Pereira, G Luikart BMC bioinformatics 9 (1), 323, 2008 | 1382 | 2008 |
| Sotagliflozin in patients with diabetes and chronic kidney disease DL Bhatt, M Szarek, B Pitt, CP Cannon, LA Leiter, DK McGuire, JB Lewis, ... New England Journal of Medicine 384 (2), 129-139, 2021 | 1261 | 2021 |
| Thrombin-receptor antagonist vorapaxar in acute coronary syndromes P Tricoci, Z Huang, C Held, DJ Moliterno, PW Armstrong, F Van de Werf, ... New England Journal of Medicine 366 (1), 20-33, 2012 | 948 | 2012 |
| Diagnosis and treatment of acute coronary syndromes: a review DL Bhatt, RD Lopes, RA Harrington Jama 327 (7), 662-675, 2022 | 914 | 2022 |
| Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021 ME Oster, DK Shay, JR Su, J Gee, CB Creech, KR Broder, K Edwards, ... Jama 327 (4), 331-340, 2022 | 809 | 2022 |
| Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial SH Hohnloser, Z Hijazi, L Thomas, JH Alexander, J Amerena, M Hanna, ... European heart journal 33 (22), 2821-2830, 2012 | 791 | 2012 |
| Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes HC Gerstein, N Sattar, J Rosenstock, C Ramasundarahettige, R Pratley, ... New England journal of medicine 385 (10), 896-907, 2021 | 777 | 2021 |
| Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale RD Lopes, JH Alexander, SM Al-Khatib, J Ansell, R Diaz, JD Easton, ... American heart journal 159 (3), 331-339, 2010 | 631 | 2010 |
